Truist analyst Asthika Goonewardene raised the firm’s price target on Autolus Therapeutics to $9 from $6 and keeps a Buy rating on the shares. Obe-cel is positioned to be a new standard of care, and the preferred CAR-T in adult ALL over Tecartus, the analyst tells investors in a research note, adding that Autolus is on track to get its first CAR-T approved next year, with favorable manufacturing and logistics set in place.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AUTL:
- Autolus Therapeutics Reports Second Quarter 2023 Financial Results and Operational Progress
- Autolus Therapeutics reports Q2 EPS (26c), consensus (22c)
- Autolus Therapeutics announces appointment of Robert F. Dolski as Chief Financial Officer
- Autolus Therapeutics appoints Dolski as CFO, Hersberger, Neville as SVPs
- Autolus Therapeutics to report second quarter 2023 financial results and host conference call on August 3, 2023